Adhering to the vision of "innovation for the great majority", Qyuns Therapeutics focuses on the research and development, industrialization and commercial expansion of antibody drugs in the fields of autoimmune and allergic diseases, and strives to solve the problems of drug accessibility and affordability. Based on the complete independent innovation capability, the company has formed a product pipeline of more than 10 innovative products, of which 7 products are in the clinical trial stage, covering psoriasis, atopic dermatitis, ankylosing spondylitis, inflammatory bowel disease, systemic lupus erythematosus, asthma and other related diseases.
The high-profile "2022 China's Pharmaceutical R&D Strength Ranking Series" in the pharmaceutical industry was released recently. With its outstanding R&D capabilities and outstanding inno...
On May 28, Qyuns was invited to participate in the 2021 annual summary and commendation conference of Taizhou Medical High-tech Zone and was awarded the "Top 10 Innovation and Entrepreneurship Enterpr...
Copyright © 2019 Qyuns Therapeutics Co., Ltd. All Rights Reserved.苏ICP备19035469号
苏公网安备 32120502010156号
